Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: A CTLA-4 blocking strategy based on Nanobody in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects

Fig. 5

In vivo antitumor activities of Nb36-treated DC-CIK cells in the established subcutaneous human tumor xenografts. A The tumor growth curves. Nb36-treated DC-CIK cells significantly reduced tumor volume. n = 6, *** P < 0.001. B The survival of tumor-bearing mice. Nb36-treated DC-CIK cells prolonged the survival of tumor-bearing mice. n = 6, *** P < 0.001. C Quantitative analysis of KI-67 expression. Data are representative images (magnification × 400) or expressed as the mean ± SD from 5 randomly selected fields of thin tumor sections. n = 6, ***P < 0.001

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us